Skip to content
Gain Therapeutics Inc

Greenlight Capital Gain Therapeutics Inc transactions over time

GANX

Gain Therapeutics Inc historical holders

total: 1

Transactions details

Total transactions:
3
New positions:
1
Added:
1
Reduced:
1
Held for:
0 quarters
Latest activity:
2024 Q1
David Einhorn has been an institutional investor in Gain Therapeutics Inc (GANX) since 2021 Q1. According to 2026 Q3 report, David Einhorn holds 566,130 shares with a market value of roughly $979.40K representing 0.03% of their equity portfolio. The fund/company first acquired GANX in 2021 Q1, initially purchasing 546,560 shares. Since the initial investment, Greenlight Capital has made 2 more transactions in this position.

Does David Einhorn still hold GANX?

Yes, David Einhorn continues to hold Gain Therapeutics Inc (GANX). According to their 2026 Q3 report, they maintain a position of 566,130 shares valued at approximately $979.40K, representing 0.03% of their equity portfolio.

When did David Einhorn first invest in GANX?

David Einhorn first invested in Gain Therapeutics Inc (GANX) in 2021 Q1 at the reported quarter-end price of $14.92 per share, acquiring 546,560 shares in their initial purchase.

GANX transactions history by Greenlight Capital

3 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2024 Q1
0.10%
566,130
$3.77
$2,134,310
-3.79% (-22,280)
-0%
2023 Q3
0.11%
588,410
$3.28
$1,929,985
+7.66% (+41,850)
+0.01%
2021 Q1
0.57%
546,560
$14.92
$8,155,000
new
+0.57%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.